Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

LogicBio Therapeutics

Request full access

Develops gene therapy vectors for previously incurable genetic and infectious diseases including hemophilia, HIV/AIDS, and methylmalonic acidemia

Cambridge, United StatesFounded 2015Biotech & Life Sciences

About LogicBio Therapeutics

LogicBio Therapeutics, Inc. is a biotechnology company focused on developing genetic medicines to treat rare and serious genetic diseases. The company aims to provide one-time treatments that offer long-lasting results, significantly improving the lives of young patients. LogicBio operates in the healthcare and biotechnology market, specifically targeting rare genetic disorders that currently have limited treatment options.

The company's business model revolves around harnessing the natural DNA repair process to create precise, stable, and durable therapies. This approach involves using advanced genetic engineering techniques to correct genetic defects at their source. By focusing on one-time treatments, LogicBio aims to reduce the need for ongoing medical interventions, thereby offering a more efficient and potentially cost-effective solution for patients and healthcare providers.

LogicBio primarily serves patients with rare genetic diseases, a market that is often underserved due to the complexity and high costs associated with developing treatments for small patient populations. The company collaborates with healthcare providers, research institutions, and pharmaceutical companies to bring its therapies from the research stage to clinical application.

Revenue generation for LogicBio comes from several streams, including partnerships with larger pharmaceutical companies, grants, and potential future sales of its genetic therapies. By presenting at industry conferences like the Jefferies Virtual Healthcare Conference, LogicBio aims to attract investment and foster collaborations that can accelerate the development and commercialization of its treatments.

In summary, LogicBio Therapeutics is dedicated to delivering innovative genetic medicines that offer hope and tangible benefits to patients with rare genetic diseases. The company's focus on one-time, durable treatments positions it as a promising player in the biotechnology sector.

Source: Dealroom company data

At a glance

Status
Listed
Listing
IPO 2018

LogicBio Therapeutics in the Cambridge ecosystem

Live from Dealroom

The LogicBio Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

7 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A5 investors entered at this stage

  • OrbiMed
  • Arix Bioscience
  • SBI Japan-Israel Innovation Fund
  • Andera Partners
  • Pontifax Funds

Series B and later2 investors entered at this stage

  • Oxford Finance
  • Poalim Capital Markets
Team profiled 13 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators 1 quality Hidden — book a demo/100
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Cambridge HQ
Book a demo for the full country breakdown

Patents

Estimated portfolio value
$2M

12 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

See LogicBio Therapeutics on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.